ProPhase Labs (PRPH) Competitors $0.61 -0.04 (-6.52%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRPH vs. OSTX, INCR, DBVT, ONCY, BYSI, VNRX, CNTB, ATRA, MURA, and SPROShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include OS Therapies (OSTX), InterCure (INCR), DBV Technologies (DBVT), Oncolytics Biotech (ONCY), BeyondSpring (BYSI), VolitionRx (VNRX), Connect Biopharma (CNTB), Atara Biotherapeutics (ATRA), Mural Oncology (MURA), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. OS Therapies InterCure DBV Technologies Oncolytics Biotech BeyondSpring VolitionRx Connect Biopharma Atara Biotherapeutics Mural Oncology Spero Therapeutics ProPhase Labs (NASDAQ:PRPH) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Do institutionals & insiders have more ownership in PRPH or OSTX? 9.4% of ProPhase Labs shares are held by institutional investors. 20.7% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in PRPH or OSTX? ProPhase Labs received 111 more outperform votes than OS Therapies when rated by MarketBeat users. However, 100.00% of users gave OS Therapies an outperform vote while only 50.00% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformProPhase LabsOutperform Votes11450.00% Underperform Votes11450.00% OS TherapiesOutperform Votes3100.00% Underperform VotesNo Votes Which has stronger valuation and earnings, PRPH or OSTX? OS Therapies has lower revenue, but higher earnings than ProPhase Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$12.75M1.14-$16.78M-$1.26-0.48OS TherapiesN/AN/A-$7.79MN/AN/A Is PRPH or OSTX more profitable? OS Therapies has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. OS Therapies' return on equity of 0.00% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase Labs-217.64% -62.92% -30.22% OS Therapies N/A N/A -569.57% Does the media prefer PRPH or OSTX? In the previous week, OS Therapies had 1 more articles in the media than ProPhase Labs. MarketBeat recorded 1 mentions for OS Therapies and 0 mentions for ProPhase Labs. OS Therapies' average media sentiment score of 0.67 beat ProPhase Labs' score of 0.00 indicating that OS Therapies is being referred to more favorably in the news media. Company Overall Sentiment ProPhase Labs Neutral OS Therapies Positive Do analysts rate PRPH or OSTX? ProPhase Labs presently has a consensus target price of $11.00, indicating a potential upside of 1,701.80%. OS Therapies has a consensus target price of $8.00, indicating a potential upside of 101.51%. Given ProPhase Labs' higher possible upside, equities analysts plainly believe ProPhase Labs is more favorable than OS Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00OS Therapies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 SummaryOS Therapies beats ProPhase Labs on 8 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.58M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.4810.5990.0517.18Price / Sales1.14195.801,117.00116.99Price / CashN/A57.1642.9637.86Price / Book0.225.094.784.78Net Income-$16.78M$151.83M$120.31M$225.60M7 Day Performance-6.22%-2.13%-1.92%-1.23%1 Month Performance-21.42%-3.10%11.50%3.36%1 Year Performance-86.84%11.54%30.59%16.60% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs3.1815 of 5 stars$0.61-6.5%$11.00+1,701.8%-86.5%$14.58M$12.75M-0.48130High Trading VolumeOSTXOS TherapiesN/A$3.09+2.3%$8.00+158.9%N/A$65.63MN/A0.00N/AGap UpINCRInterCure0.1035 of 5 stars$1.43+8.2%N/A+16.4%$64.94M$272.67M0.00350News CoverageGap UpDBVTDBV Technologies3.5378 of 5 stars$3.13-12.3%$22.50+618.8%-66.8%$64.38M$15.73M-0.73106Gap DownONCYOncolytics Biotech1.9125 of 5 stars$0.83+1.4%$4.00+384.8%-33.0%$63.58MN/A-3.0030News CoverageBYSIBeyondSpringN/A$1.58-3.5%N/A+72.8%$61.76M$1.88M0.0080Positive NewsGap DownVNRXVolitionRx1.7492 of 5 stars$0.67+17.7%$3.75+463.9%+2.4%$61.63M$770,000.00-1.5780Gap UpCNTBConnect Biopharma3.4741 of 5 stars$1.09-2.5%$8.00+633.9%+11.9%$60.23M$24.12M0.00110Positive NewsGap DownATRAAtara Biotherapeutics3.8375 of 5 stars$10.45+1.2%$16.67+59.5%-17.6%$60.19M$100.44M-0.40165Analyst ForecastNews CoverageGap UpMURAMural Oncology3.0856 of 5 stars$3.48-4.4%$16.00+359.8%-9.1%$59.23MN/A-0.40119Negative NewsGap UpSPROSpero Therapeutics4.5453 of 5 stars$1.08+0.9%$5.00+363.0%-29.3%$58.88M$103.78M15.2946Analyst DowngradeNews Coverage Related Companies and Tools Related Companies OSTX Competitors INCR Competitors DBVT Competitors ONCY Competitors BYSI Competitors VNRX Competitors CNTB Competitors ATRA Competitors MURA Competitors SPRO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRPH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
